Form 4: Neuronetics Insider Buys 100,000 Shares
Statement of Changes in Beneficial Ownership
Jorey Chernett, a Director at Neuronetics, Inc., acquired 100,000 shares of common stock on May 19, 2026, at a price of $1.17 per share.
Summary
- Jorey Chernett, a Director and 10% owner of Neuronetics, Inc., purchased 100,000 shares of common stock on May 19, 2026.
- The purchase was made at a price of $1.17 per share.
- Following this transaction, Chernett beneficially owns 10,553,988 shares of common stock.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive development due to a significant insider purchase, indicating strong confidence from a key stakeholder.
Positives
- Significant share acquisition by a key insider (Director and 10% owner) indicates confidence in the company's future prospects.
- The purchase of 100,000 shares at $1.17 per share suggests a belief that the current stock price is undervalued.
Future Outlook
No specific forward-looking statements or guidance are provided in this Form 4 filing, which solely reports a change in beneficial ownership.
Industry Context
StockSavvy.ai notes that insider buying, particularly by directors and significant shareholders, is often interpreted as a positive signal by the market, suggesting a belief in the company's intrinsic value and future growth potential within the medical technology sector.
Stakeholder Impact
- Shareholders may view this insider purchase positively, potentially leading to increased confidence and a favorable impact on share price.
- Management and employees may be encouraged by the visible commitment of a key insider.
Key Dates
| Date | Description |
|---|---|
| 05/19/2026 | Transaction date for the acquisition of 100,000 common shares by Jorey Chernett. |
| 05/20/2026 | Date of the signature on the Form 4 filing. |
Recommendation
holdWhile insider buying is a positive signal, this Form 4 filing only reports a single transaction by one individual and does not provide comprehensive financial or strategic updates. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor for further developments and broader company performance indicators before making significant investment decisions.
Keywords
Neuronetics, STIM, Form 4, Insider Trading, Stock Purchase, Director, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.